Medplus Health Services reported a 15-day drug license suspension for a subsidiary store by the FDA, with an estimated financial impact of ₹0.14 Crore.
Medplus Health Services reported a one-day drug license suspension at a Telangana store due to compliance violations. The estimated financial impact is Rs 0.001 Crore.
Medplus Health's subsidiary, Optival Health, received a 4-day drug license suspension at its Udala, Odisha store. The financial impact is estimated at Rs 0.02 Crore.
MedPlus Health Services reported a 7-day drug license suspension for its subsidiary Optival Health Solutions. The action carries an estimated financial impact of Rs 0.12 Crore.
Value
₹0.12 Cr
From
Assistant Director Drugs Control Administration, Mangalore Circle
The Food & Drug Administration suspended the drug license of a MedPlus subsidiary store in Nashik for 15 days. The expected financial impact is Rs 0.042 Crore.
MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.
Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
Medplus Health Services reported a 5-day suspension of a drug license at a Mangalore store due to compliance issues. The expected financial impact is ₹0.03 Crore.
MedPlus Health Services has filed board comments regarding a fine levied by the exchanges for non-compliance with Regulation 17(1A) of SEBI LODR Regulations, 2015.
The Drugs Control Administration suspended the drug license of Medplus's subsidiary, Optival Health Solutions, for five days. The financial impact of this suspension is ₹0.02 Crore.
Medplus Health reported temporary drug license suspensions at three pharmacy stores, with a financial impact of ₹0.07 Crore. A prior suspension in Pune was stayed.
Medplus Health Services reported drug license suspensions for three of its subsidiary's stores due to regulatory violations, with an estimated financial impact of ₹0.06 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, received a 2-day drug license suspension at a specific store for minor regulatory non-compliance.
Medplus Health Services' subsidiary, Optival Health Solutions, faces temporary drug license suspensions for four stores in Karnataka due to regulatory non-compliance.
MedPlus Health Services reported a 7-day drug license suspension for a subsidiary store in Andhra Pradesh due to regulatory non-compliance. The financial impact is ₹0.03 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, faced a two-day drug license suspension at a Karnataka store. The regulatory action impacts operations by Rs 0.0071 Crore.
Medplus Health's subsidiary, Optival Health Solutions, received a 5-day suspension of its drug license at a Hanamkonda store due to regulatory violations. The financial impact is negligible.
